Skip to main content

Table 1 Patient Characteristics by Cystic Fibrosis Transmembrane Regulator Mutation Status

From: A survey identifying nutritional needs in a contemporary adult cystic fibrosis cohort

  All Eligible Patients N = 66 CFTR Mutation Class I-III N = 54 CFTR Mutation Class IV-V N = 12  
Variable Observed N Observed N Observed N p Value
Age – mean (SD), years 32.3 (11.4) 66 30.4 (8.8) 54 40.8 (17.2) 12 0.0637
Male gender 32 (48.5) 66 27 (50.0) 54 5 (41.7) 12 0.601
Medicaid Insurance 23 (35.4) 65 17 (32.1) 53 6 (50.0) 12 0.241
CFTR mutation status   66      
Homozygous Class I-III 54 (81.8)       
Heterozygous Class I-III 12 (18.2)       
Homozygous Class IV-V 0 (0)       
FEV1 - % predicted (SD) 59.3 (23.3) 66 57.3 (22.7) 54 68.3 (24.9) 12 0.178
Weight – mean (SD), kg 66.1 (14.6) 66 63.9 (11.9) 54 76.0 (21.2) 12 0.079
BMI – mean (SD), kg/m2 23.4 (4.3) 66 22.8 (3.5) 54 26.2 (6.4) 12 0.099
BMI < 18.5 9 (13.6) 66 7 (13.0) 54 2 (16.7) 12 0.663b
BMI 18.5–24.99 38 (57.6) 66 34 (63.0) 54 4 (33.3) 12 0.104b
BMI 25–29.99 13 (19.7) 66 11 (20.4) 54 2 (16.7) 12 1.000b
BMI ≥ 30 6 (9.1) 66 2 (3.7) 54 4 (33.3) 12 0.008 b
BMI meeting CFF goala 38 (57.6) 66 29 (53.7) 54 9 (75.0) 12 0.177b
CF-related diabetes on insulin 15 (23.1) 65 14 (26.4) 53 1 (8.3) 12 0.267b
CF-related PI on enzymes 58 (89.2) 65 52 (98.1) 53 6 (50.0) 12 < 0.001 b
Prednisone use (at time of survey) 5 (7.7) 65 5 (9.4) 53 0 (0) 12 0.575b
PEG tube in place 2 (3.1) 65 1 (1.9) 53 1 (8.3) 12 0.338b
Nutritional supplement use 32 (49.2) 65 26 (49.1) 53 6 (50.0) 12 0.953
  1. Data are presented as No. (%) unless indicated otherwise. Certain background clinical data were not recorded and were thus unavailable for one individual
  2. aCFF goal for weight is BMI ≥22 kg/m2 for females, and ≥ 23 kg/m2 for males
  3. b= Fisher’s exact test
  4. CF cystic fibrosis, SD standard deviation, CFTR cystic fibrosis transmembrane conductance regulator gene, FEV1 forced expiratory volume in one second, BMI body mass index, CFF Cystic Fibrosis Foundation, PI pancreatic insufficiency, PEG percutaneous endoscopic gastrostomy